Related Experiment Video
Updated: May 10, 2026
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Lipid-lowering agents.
Mfon Ewang-Emukowhate1, Anthony S Wierzbicki
1Department of Chemical Pathology, Guy's & St Thomas Hospitals, St Thomas' Hospital Campus, London, England. Mfon.Ewang@gstt.nhs.uk
Summary
Lipid-lowering therapies, including statins, are crucial for reducing cardiovascular disease (CVD) risks. For patients unresponsive to statins, novel agents and existing alternatives offer further treatment options.
Area of Science:
- Cardiology
- Pharmacology
- Genetics
Background:
- Lipid lowering significantly reduces cardiovascular disease (CVD) mortality and morbidity.
- Low-density lipoprotein cholesterol (LDL-C) reduction is key for preventing coronary heart disease and stroke.
- Statins are primary treatments, but some patients require alternative therapies due to intolerance or lack of efficacy.
Purpose of the Study:
- To review current lipid-lowering medications and their clinical trial data.
- To discuss novel therapeutic agents under development for lipid management.
- To present data on gene therapy for specific lipid disorders.
Main Methods:
- Literature review of clinical trial data for lipid-lowering drugs.
- Analysis of pharmacology and indications for various medication classes.
- Examination of human trial data for emerging therapies.
Main Results:
- Established lipid-lowering drugs (statins, fibrates, resins, omega-3s) have defined roles and efficacy.
- Novel agents like mipomersen, lomitapide, CETP inhibitors, and PCSK9 inhibitors show promise.
- Gene therapy for lipoprotein lipase deficiency is available.
Conclusions:
- A range of lipid-lowering therapies exist, from traditional drugs to novel agents.
- Treatment selection depends on individual patient risk, LDL-C targets, and drug response.
- Ongoing research and development continue to expand options for managing dyslipidemia and CVD risk.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:25Blood Studies for Cardiovascular System III: Serum Lipid Profile
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...